http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105294680-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6ed83b9d5c28c6c356d1d08d58501e7 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 2014-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4d083377b3305ce568028006b4fcd11 |
| publicationDate | 2016-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105294680-A |
| titleOfInvention | VEGFR-2 irreversible inhibitor and use thereof |
| abstract | The invention relates to use of a compound represented by a general formula I shown in the description (with a structure and a serial number as follows) or pharmaceutically acceptable salts thereof in preparation of drugs for preventing or treating diseases related to VEGFR-2 kinase irreversible inhibitors. In the general formula I, Ar represents an aromatic group including three types represented by a general formula II shown in the description, wherein * represents a locus connected with a N atom, and ** represents a connecting locus connected with a T group; the T group comprises the following 9 types (represented by a general formula III shown in the description): R represents C1-C6 substituted alkyl; n represents 0, 1 or 2; X represents O, N, S, C or a similar atom; R1, R2 and R3 respectively represents an H atom or C1-C3substituted alkyl independently; or R2 and R3 are connected together in a urea structure or form a five- or six-membered heterocycle; and Y represents CH or N or pharmaceutically acceptable salts or prodrugs or pharmaceutical compositions. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114450285-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022034587-A1 |
| priorityDate | 2014-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 137.